A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma (SYS-ACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02177110|
Recruitment Status : Active, not recruiting
First Posted : June 27, 2014
Last Update Posted : February 26, 2020
This is an exploratory prospective translational multicentre study. Melanoma is the 5th most common cancer diagnosed in Ireland and its incidence among women and men is above the European average.
Following treatment the elimination of cancer cells ultimately occurs by the activation of apoptotic cell death pathways. The SYS-ACT approach builds on a combination of mathematical systems of modelling, quantitative biochemistry and cell biology, and specifically predicts the drug responsiveness of melanoma cell lines to various apoptosis-inducing treatments.
The investigators propose to validate the SYS-ACT approach and application in a translational systems medicine study.
|Condition or disease|
|Advanced Melanoma Metastatic Melanoma|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Responsiveness in Advanced or Metastatic Malignant Melanoma (SYS-ACT)|
|Actual Study Start Date :||September 2014|
|Estimated Primary Completion Date :||August 2020|
|Estimated Study Completion Date :||August 2020|
Patients who have fresh frozen and FFPE tissue taken prior to treatment
Fresh frozen tissue and FFPE tissue is available
- Validation of SYS-ACT [ Time Frame: 2 years ]Validate the predictive capacity of SYS-ACT by assessing responsiveness to treatment
- Progression free survival [ Time Frame: 2 years ]Progression free survival (PFS) and overall survival will be assessed for each patient for up to 2 years.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02177110
|Cork University Hospital|
|Mater Misericordiae University Hospital and Mater Private Hospital|
|St Vincent's University Hospital|
|Galway University Hospital|
|Waterford Regional Hospital|